Analytical Techniques for Antibody-Drug Conjugates: Comprehensive Insights

Antibody-drug conjugates (ADCs) are a cutting-edge class of biopharmaceuticals that combine the selectivity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. This targeted delivery system has redefined oncology treatment by reducing systemic toxicity and improving efficacy. ADCs are composed of a tumor-targeting antibody, a cytotoxic agent, and a chemical linker, which together create a complex structure that presents various analytical challenges. These challenges include determining the drug-to-antibody ratio (DAR), ensuring specificity at the conjugation site, and assessing the stability of the linker, all of which significantly influence pharmacokinetics, pharmacodynamics, and potential toxicity. This review highlights critical analytical techniques necessary for the characterization of ADCs, emphasizing their physicochemical properties, biological activity, stability assessments, and regulatory implications. Employing robust analytical methods is essential throughout the ADC development process to guarantee both therapeutic effectiveness and safety, ultimately positioning ADCs as a vital element in contemporary cancer treatment strategies.